Artiva Biotherapeutics appoints Alison Moore, Ph.D., to Its Board of Directors

Artiva Biotherapeutics (ARTV) announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer CTO of Codexis (CDXS), a leading enzyme engineering company, and was the former CTO of Allogene Therapeutics (ALLO), a pioneering clinical-stage company advancing CAR T-cell therapies. “We are honored to welcome Alison to the Artiva Board of Directors. Her decades of executive experience in manufacturing and technical operations across modalities, specifically in allogenic cell therapies, will bring an important perspective to our team as we advance our pipeline in the clinic,” said Fred Aslan, M.D., CEO of Artiva. “In parallel to our efforts to evaluate the efficacy and safety of AlloNK we believe the extensive history of our manufacturing process sets us apart from our allogeneic cell therapy peers, potentially accelerating our path to bring this experimental therapy to patients.”